[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350295-105":59,"doc-detail-350295-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","twenty-year-results-of-the-randomized-european-organization-for-research-and-treatment-of-cancer-trial-2292210925-evaluating-internal-mammary-chain-and-medial-supraclavicular-lymph-node-irradiation-in-stage-i-iii-breast-cancer","Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer","","European Organization for Research and Treatment of Cancer trial EORTC 22922/10925 assessed internal mammary and medial supraclavicular (IM-MS) lymph node irradiation (IM-MS-RT) in stage I–III breast cancer. Eligible patients had involved axillary nodes and/or centrally/medially located tumors. Overall survival was the primary endpoint, with disease-free survival, distant metastases-free survival, breast cancer mortality, and any breast recurrence as secondary endpoints. From 1996–2004, 4004 patients were randomized; at a median 22.2-year follow-up, long-term survival effects differed across endpoints.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/twenty-year-results-of-the-randomized-european-organization-for-research-and-treatment-of-cancer-trial-2292210925-evaluating-internal-mammary-chain-and-medial-supraclavicular-lymph-node-irradiation-in-stage-i-iii-breast-cancer/350295/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/twenty-year-results-of-the-randomized-european-organization-for-research-and-treatment-of-cancer-trial-2292210925-evaluating-internal-mammary-chain-and-medial-supraclavicular-lymph-node-irradiation-in-stage-i-iii-breast-cancer/350295.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What did the EORTC 22922/10925 trial evaluate in stage I–III breast cancer?","Question",{"text":112,"@type":113},"It evaluated whether internal mammary and medial supraclavicular lymph node irradiation (IM-MS-RT) improves outcomes compared with the control approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the primary and key secondary endpoints?",{"text":117,"@type":113},"Overall survival was the primary endpoint, while secondary endpoints included disease-free survival, distant metastases-free survival, breast cancer mortality, and any breast recurrence.",{"name":119,"@type":110,"acceptedAnswer":120},"How long was the follow-up and what overall survival result was reported at 20 years?",{"text":121,"@type":113},"At a median follow-up of 22.2 years, the 20-year overall survival was 61.8% in the control group versus 61.0% in the IM-MS-RT group, with a hazard ratio of 1.00 (p=.967).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350295,1790498768,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","DOI: 10. 3322/caac.70082  \nARTICLE  \nTwenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer  \nOrit Kaidar-Person MD, PhD1,2  | Caroline G. Weltens MD, PhD3,4  |  \nCatherine Fortpied MSc5 | Luc J. E. E. Scheijmans MD6  | Carine Y. Kirkove MD7  | Volker Budach MD, PhD8,9  | Karine Peignaux-Casasnovas MD 10  |  \nMariacarla Valli MD11, 12  | Max Peters MD, MSc, PhD13  |  \nFemke van der Leij MD, PhD 14  | Sofia Rivera MD, PhD 15 | Nicola Weidner MD16 | Desirée H. J. G. van den Bongard MD, PhD17  | Claudia Linsenmeier MD 18 | Roxolyana Abdah-Bortnyak MD 19  | Shaymaa Hosni MD20 | Eveline Koiter MD21 | Antoine M. Engelen MD6 | Adinda Baten MD3,4  | Lydia Champezou MSc5  | Alain Fourquet MD22 | Harry G. M. M. Bartelink MD, PhD23 |  \nHenk Struikmans MD, PhD24 | Philip M. P. Poortmans MD, PhD25,26  |  \nfor the European Organization for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups  \nCorrespondence  \nPhilip M. P. Poortmans, Department of Radiation Oncology, Iridium Netwerk, Oosterveldlaan 22, 2610 Antwerp, Belgium. Email: [philip.poortmans@telenet.be](philip.poortmans@telenet.be); [philip.poortmans@zas.be](philip.poortmans@zas.be)  \nFunding information  \nKom op tegen Kanker; EORTC Cancer Research Fund; KWF Kanker Bestrijding; Ligue Contre le Cancer  \nAbstract  \nEuropean Organization for Research and Treatment of Cancer trial EORTC 22922/ 10925 evaluated internal mammary and medial supraclavicular (IM-MS) lymph node irradiation (IM-MS-RT) in patients with stage I–III breast cancer. Eligible patients had involved axillary nodes and/or centrally/medially located tumors regardless of nodal involvement. The primary end point was overall survival, secondary end points were disease-free survival, distant metastases-free survival, breast cancer mortality, and any breast recurrence. Between 1996 and 2004, 4004 patients were randomized. The median patient age was 54 years. At a median follow-up of 22.2 years, 1550 (38.7%) patients died, of whom 796 (51.4%) died from breast cancer. At 20 years, the overall survival rate was 61.8% in the control group versus 61.0% in the IM-MS-RT group (hazard ratio [HR], 1.00; p = . 967); the disease-free survival rate was 49.0% versus 48. 2%, respectively (HR, 0. 97; p = . 515); and the distant metastases-free survival rate  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCA Cancer J Clin. 2026;e70082.  \n[https://doi.org/10.3322/caac.70082](https://doi.org/10.3322/caac.70082)  \nwi[leyonlinelibrary.com/journal/caac](leyonlinelibrary.com/journal/caac)  \n1 of 14  \nwas 59.8% versus 58. 9%, respectively (HR, 0. 97; p = . 578). The breast cancer mortality rate was 22.4% in the control group and 18. 6% in the IM-MS-RT group (HR, 0.82; p = .006), whereas the rate of deaths not from breast cancer or from unknown causes was 15.8% versus 20.4%, respectively (HR, 1. 26; p = .002). Lung fibrosis, cardiac fibrosis, and cardiac diseases were more frequent after IM-MS-RT versus no IM-MS-RT (6.3% vs. 3. 2%, 2. 7% vs. 1. 7%. and 15. 2% vs. 11. 7%, respectively); and the rates of severe cardiac and lung morbidities (scores of 3 or 4) were 1. 9% versus 1. 7% and 0. 3% versus 0.0%, respectively. Breast cancer mortality at 20 years was statistically significantly lower after IM-MS-RT, but deaths not from breast cancer increased after 15 years, resulting in no long-term benefit of IM-MS-RT on overall survival. Therefore, the authors strongly call for very long-term follow-","cbCaihO998NdvRT9","https://ap.wps.com/l/cbCaihO998NdvRT9","pdf",2839481,14,"English","# Abstract\n# Introduction","[{\"question\":\"What did the EORTC 22922/10925 trial evaluate in stage I–III breast cancer?\",\"answer\":\"It evaluated whether internal mammary and medial supraclavicular lymph node irradiation (IM-MS-RT) improves outcomes compared with the control approach.\"},{\"question\":\"What were the primary and key secondary endpoints?\",\"answer\":\"Overall survival was the primary endpoint, while secondary endpoints included disease-free survival, distant metastases-free survival, breast cancer mortality, and any breast recurrence.\"},{\"question\":\"How long was the follow-up and what overall survival result was reported at 20 years?\",\"answer\":\"At a median follow-up of 22.2 years, the 20-year overall survival was 61.8% in the control group versus 61.0% in the IM-MS-RT group, with a hazard ratio of 1.00 (p=.967).\"}]","Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer | PDF",1790088282,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de8e21c30ddc1e13433b10777a697ae1.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d853791c12ade3fc0fc1a79747a05fa.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47375562de87fd6f943ac128232a3c3b.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc6c9920b28c1385d50cd48831f653fd.webp",980,1287]